TB
MCID: TBR010
MIFTS: 70

Tuberculosis (TB) malady

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Tuberculosis

Aliases & Descriptions for Tuberculosis:

Name: Tuberculosis 12 50 52 41 3 3 3 42 14 69
Tb 50 45 3
Tuberculoma 42 69
Tuberculosis, Susceptibility to 13
Kochs Disease 50

Classifications:



External Ids:

Disease Ontology 12 DOID:399
SNOMED-CT 64 15202009
ICD10 33 A15-A19 A17.9
UMLS 69 C0041295

Summaries for Tuberculosis

MedlinePlus : 41 tuberculosis (tb) is a disease caused by bacteria called mycobacterium tuberculosis. the bacteria usually attack the lungs, but they can also damage other parts of the body. tb spreads through the air when a person with tb of the lungs or throat coughs, sneezes, or talks. if you have been exposed, you should go to your doctor for tests. you are more likely to get tb if you have a weak immune system. symptoms of tb in the lungs may include a bad cough that lasts 3 weeks or longer weight loss loss of appetite coughing up blood or mucus weakness or fatigue fever night sweats skin tests, blood tests, x-rays, and other tests can tell if you have tb. if not treated properly, tb can be deadly. you can usually cure active tb by taking several medicines for a long period of time. nih: national institute of allergy and infectious diseases

MalaCards based summary : Tuberculosis, also known as tb, is related to pulmonary tuberculosis and tuberculous peritonitis, and has symptoms including fatigue, fever and weight loss. An important gene associated with Tuberculosis is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Priftin and Sirturo have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

NIH Rare Diseases : 50 tuberculosis (tb) is a contagious and often severe airborne disease caused by the tb bacterium, mycobacterium tuberculosis. tb typically affects the lungs, but other organs of the body may be involved, as well. not everyone who is infected with the tb bacterium becomes sick. tb bacterial infections only become "active disease" if the immune system can't stop them from growing. classic signs and symptoms of active tb can include cough, weight loss, fever, night sweats, hemoptysis, chest pain, and fatigue. symptoms involving areas of the body other than the lungs vary depending on which organ(s) are affected. tb is usually treated with a regimen of medications taken over a long period of time (often six to twelve months). last updated: 2/4/2016

Disease Ontology : 12 A primary bacterial infectious disease that is located in lungs, located in lymph nodes, located in pericardium, located in brain, located in pleura or located in gastrointestinal tract, has material basis in Mycobacterium tuberculosis, which is transmitted_by droplets released into the air when an infected person coughs or sneezes.

Wikipedia : 71 Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB).... more...

Related Diseases for Tuberculosis

Diseases related to Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 891)
id Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 33.8 IFNG IL10 TLR4 TLR6 TNF
2 tuberculous peritonitis 31.9 IL10 TLR9 TNF
3 mikulicz disease 31.3 IL1B TLR4 TLR9 TNF
4 hepatitis 31.0 IFNG IL10 TNF
5 choroiditis 30.2 IL10 IL1B TLR4 TNF
6 intussusception 30.1 IL1B TNF
7 neuropathy 29.9 IL1B TLR4 TNF
8 pyelonephritis 29.8 IL10 IL1B TNF
9 asbestosis 29.8 HSPD1 IL10 TLR2 TNF
10 aseptic meningitis 29.6 TLR2 TLR4 TNF
11 histiocytosis 29.6 HSPD1 IL1B TLR2 TLR4 TNF
12 rheumatoid arthritis 29.6 HSPD1 IFNG IL10 IL18 IL1B MIF
13 tularemia 29.5 IFNG IL10 TLR9 TNF
14 nasopharyngitis 29.5 IFNG IL1B TLR9 TNF
15 fasciitis 29.4 CTSG TLR2 TNF
16 pulmonary eosinophilia 29.4 IFNG IL10 IL1B TLR2 TLR9 TNF
17 nonspecific interstitial pneumonia 29.3 IFNG IL10 TLR9 TNF
18 chronic lymphocytic leukemia 29.3 IFNG IL1B TLR9 TNF
19 polyarteritis nodosa 29.3 IFNG TLR2 TLR4 TLR9
20 rift valley fever 29.2 IFNG IFNGR1 IL1B SLC11A1 TLR4 TNF
21 glucose intolerance 29.2 B2M IFNG IL18 TNF
22 miliary tuberculosis 12.4
23 urogenital tuberculosis 12.2
24 gastrointestinal tuberculosis 12.2
25 pleural tuberculosis 12.2
26 skeletal tuberculosis 12.2
27 laryngeal tuberculosis 12.2
28 multidrug-resistant tuberculosis 12.2
29 lymph node tuberculosis 12.2
30 renal tuberculosis 12.1
31 hepatic tuberculosis 12.1
32 extrapulmonary tuberculosis 12.1
33 intestinal tuberculosis 12.1
34 central nervous system tuberculosis 12.1
35 splenic tuberculosis 12.1
36 oral tuberculosis 12.1
37 bladder tuberculosis 12.1
38 abdominal tuberculosis 12.1
39 esophageal tuberculosis 12.1
40 mycobacterium tuberculosis, susceptibility to mycobacterium tuberculosis, protection against, included 12.1
41 pericardial tuberculosis 12.0
42 ureter tuberculosis 11.9
43 cardiac tuberculosis 11.9
44 mycobacterium tuberculosis 3 11.8
45 mycobacterium tuberculosis 2 11.7
46 mycobacterium tuberculosis, susceptibility to infection by 11.7
47 tuberculous meningitis 11.6
48 tuberculous epididymitis 11.4
49 aspergillosis 11.1
50 brown-sequard syndrome 11.1

Graphical network of the top 20 diseases related to Tuberculosis:



Diseases related to Tuberculosis

Symptoms & Phenotypes for Tuberculosis

Human phenotypes related to Tuberculosis:

32
id Description HPO Frequency HPO Source Accession
1 fatigue 32 HP:0012378
2 fever 32 HP:0001945
3 weight loss 32 HP:0001824
4 abnormality of lung morphology 32 HP:0002088
5 cough 32 HP:0012735

UMLS symptoms related to Tuberculosis:


coughing, fever, pruritus, snoring

GenomeRNAi Phenotypes related to Tuberculosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.98 IL10 CD209 IL1B HSPD1 MIF
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.98 IL1B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.98 CD209
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.98 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.98 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.98 HSPD1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.98 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.98 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.98 HSPD1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.98 CD209 MIF
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.98 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.98 MIF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.98 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.98 HSPD1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.98 IL1B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.98 IL1B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.98 CD209
18 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.98 IL10 IL1B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.98 IL1B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.98 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.98 MIF IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.98 CD209
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.98 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.98 CD209
25 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.98 CD209
26 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.98 CD209 IL1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.98 IL1B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.98 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.98 HSPD1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.98 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.98 IL1B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.98 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.98 CD209 IL1B
34 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.98 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.98 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.98 HSPD1

MGI Mouse Phenotypes related to Tuberculosis:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 B2M CTSG IFNG IFNGR1 IL10 IL18
2 immune system MP:0005387 10.34 CTSG IFNG IFNGR1 IL10 IL18 IL1B
3 homeostasis/metabolism MP:0005376 10.3 B2M IFNG IFNGR1 IL10 IL18 IL1B
4 cellular MP:0005384 10.29 B2M HSPD1 IFNG IFNGR1 IL10 IL18
5 cardiovascular system MP:0005385 10.26 IFNGR1 IL10 IL18 IL1B TIRAP TLR2
6 digestive/alimentary MP:0005381 10.24 IFNGR1 IL10 IL18 SLC11A1 TLR2 TLR4
7 mortality/aging MP:0010768 10.2 TNF VDR HSPD1 IFNG IFNGR1 IL10
8 integument MP:0010771 10.1 B2M IFNG IFNGR1 IL10 IL18 IL1B
9 liver/biliary system MP:0005370 9.97 B2M CTSG IFNG IFNGR1 IL10 TLR2
10 neoplasm MP:0002006 9.9 B2M CTSG IFNG IFNGR1 IL10 IL1B
11 muscle MP:0005369 9.86 TNF VDR HSPD1 IFNG IL10 IL18
12 nervous system MP:0003631 9.73 TNF VDR B2M HSPD1 IFNG IFNGR1
13 reproductive system MP:0005389 9.32 B2M HSPD1 IFNG IFNGR1 IL10 NAT2

Drugs & Therapeutics for Tuberculosis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Priftin 17 RIFAPENTINE Hoechst Marion Roussel Approved June 1998
2
Sirturo 17 BEDAQUILINE FUMARATE Janssen Therapeutics Approved December 2012

Drugs for Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 481)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1 74-55-5 3279 14052
2
Isoniazid Approved Phase 4,Phase 3,Phase 2,Phase 1 54-85-3 3767
3
Pyrazinamide Approved Phase 4,Phase 3,Phase 2,Phase 1 98-96-4 1046
4
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
6
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
7
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 354812-41-2, 151096-09-2 152946
8
Norgestimate Approved Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
9
Rifabutin Approved Phase 4,Phase 2,Phase 3,Phase 1 72559-06-9 6323490
10
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 57-92-1 19649
11
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
12
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
13
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 134678-17-4 60825
14
Artemether Approved Phase 4 71963-77-4 119380 68911
15
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 154598-52-4 64139
16
Lumefantrine Approved Phase 4 82186-77-4 6437380
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
18
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
19
Zidovudine Approved Phase 4,Phase 3,Phase 1 30516-87-1 35370
20
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
21
Linezolid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 165800-03-3 441401
22
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 143491-57-0 60877
23
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147127-20-6 464205
24
Nelfinavir Approved Phase 4,Phase 1 159989-64-7 64143
25
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
26
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
27
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3056-17-5 18283
28
Lopinavir Approved Phase 4,Phase 2,Phase 1 192725-17-0 92727
29
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 1 155213-67-5 392622
30
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2 216974-75-3
31
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2 723-46-6 5329
32
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2 738-70-5 5578
33
Rifapentine Approved Phase 4,Phase 3,Phase 2,Phase 1 61379-65-5 6323497
34
Amikacin Approved, Vet_approved Phase 4,Phase 3,Phase 2 37517-28-5 37768
35
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1 68-41-7 401 6234
36
Calcium carbonate Approved Phase 4,Phase 3 471-34-1
37
Bedaquiline Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 843663-66-1
38
Dapsone Approved, Investigational Phase 4 80-08-0 2955
39
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
41
Etanercept Approved, Investigational Phase 4 185243-69-0
42
Methotrexate Approved Phase 4,Phase 3 1959-05-2, 59-05-2 126941
43
Ustekinumab Approved, Investigational Phase 4,Phase 2 815610-63-0
44
Aminosalicylic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1 65-49-6 4649
45
Capreomycin Approved Phase 4,Phase 3 11003-38-6 3000502
46
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2 2030-63-9 2794
47
Darunavir Approved Phase 4,Phase 1 635728-49-3, 206361-99-1 213039
48 Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1 1051375-16-6 54726191
49
Ethionamide Approved Phase 4,Phase 2,Phase 3 536-33-4 2761171
50
Kanamycin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 8063-07-8, 59-01-8 6032

Interventional clinical trials:

(show top 50) (show all 1028)
id Name Status NCT ID Phase
1 Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? Unknown status NCT00214708 Phase 4
2 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4
3 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Unknown status NCT01782950 Phase 4
4 Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination. Unknown status NCT00242047 Phase 4
5 Research on New Regimens for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4
6 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
7 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
8 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis Unknown status NCT02464683 Phase 4
9 Innovative Approaches to Tuberculosis Control Unknown status NCT00472316 Phase 4
10 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
11 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4
12 Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children Unknown status NCT00604617 Phase 4
13 Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers Unknown status NCT00311220 Phase 4
14 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4
15 Epidemiology of MDR-TB in Peru Unknown status NCT00676754 Phase 4
16 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
17 Simple Verbal Intervention for Adequately Collecting Sputum Unknown status NCT01135043 Phase 4
18 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4
19 NAT2 in Re-challenge of INH in Patients With Hepatitis Unknown status NCT00728546 Phase 4
20 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
21 Quantiferon for Detection of Latent Tuberculosis in Healthcare Workers Completed NCT00797836 Phase 4
22 Improving Community Based Tuberculosis Care in Ethiopia Completed NCT00803322 Phase 4
23 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis Completed NCT00939419 Phase 4
24 Treatment of Latent Tuberculosis Infection With Isoniazid Completed NCT00293228 Phase 4
25 QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Completed NCT01223534 Phase 4
26 Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST) Completed NCT00851630 Phase 4
27 A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy Completed NCT00402610 Phase 4
28 Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed NCT00164281 Phase 4
29 Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal Completed NCT00412009 Phase 4
30 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Completed NCT01521364 Phase 4
31 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
32 Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis Completed NCT00108862 Phase 4
33 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
34 TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB Completed NCT00023400 Phase 4
35 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4
36 Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis Completed NCT00402454 Phase 4
37 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
38 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4
39 Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis Completed NCT00617643 Phase 4
40 TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy) Completed NCT00107887 Phase 4
41 An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin Completed NCT00771498 Phase 4
42 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease Completed NCT00402402 Phase 4
43 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment Completed NCT01380080 Phase 4
44 Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB Completed NCT02348177 Phase 4
45 Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage Completed NCT00405301 Phase 4
46 Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries? Completed NCT00146302 Phase 4
47 Effect of Weight and/or Obesity on Ethambutol Drug Concentrations Completed NCT01048697 Phase 4
48 Effect of Weight and/or Obesity on Dapsone Drug Concentrations Completed NCT01165840 Phase 4
49 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697 Phase 4
50 Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea Completed NCT00864812 Phase 4

Search NIH Clinical Center for Tuberculosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: tuberculosis

Genetic Tests for Tuberculosis

Anatomical Context for Tuberculosis

MalaCards organs/tissues related to Tuberculosis:

39
Lung, T Cells, Testes, Lymph Node, Monocytes, Skin, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Tuberculosis:

18
Brain, Lungs, Pericardium, Lymph Nodes, Pleura Or

Publications for Tuberculosis

Articles related to Tuberculosis:

(show top 50) (show all 8279)
id Title Authors Year
1
Accuracy of computed tomographic features in differentiating intestinal tuberculosis from Crohn's disease: a systematic review with meta-analysis. ( 28522943 )
2017
2
Performance of Xpert MTB/RIF on Ascitic Fluid Samples for Detection of Abdominal Tuberculosis. ( 28042217 )
2017
3
Severe Pleuropulmonary Paragonimiasis Caused by Paragonimus mexicanus Treated as Tuberculosis in Ecuador. ( 27879464 )
2017
4
Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. ( 28088237 )
2017
5
Predictive Model for Differentiating Crohn's Disease and Intestinal Tuberculosis: The Story Is Incomplete Without Imaging. ( 28050042 )
2017
6
MIR144* inhibits antimicrobial responses against Mycobacterium tuberculosis in human monocytes and macrophages by targeting the autophagy protein DRAM2. ( 27764573 )
2017
7
Absorption, distribution, and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis. ( 28092695 )
2017
8
Bacteria endocarditis consolidation with vertebra bone tuberculosis: a case report. ( 28061897 )
2017
9
Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment. ( 28054732 )
2017
10
Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis. ( 28069654 )
2017
11
Significance of genetic polymorphisms in long non-coding RNA AC079767.4 in tuberculosis susceptibility and clinical phenotype in Western Chinese Han population. ( 28424495 )
2017
12
Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks. ( 28065665 )
2017
13
Oral tuberculosis. ( 27889200 )
2017
14
Murine Mycobacterium marinum Infection as a Model for Tuberculosis. ( 27914088 )
2017
15
Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty? ( 28049180 )
2017
16
Who are the patients that default tuberculosis treatment? - space matters! ( 28091336 )
2017
17
Paradoxical results of two automated real-time PCR assays in the diagnosis of pleural tuberculosis. ( 27866961 )
2017
18
Pulmonary tuberculosis presenting as post-operative fever of unknown origin. ( 28062417 )
2017
19
Meta-Analytic Bayesian Model For Differentiating Intestinal Tuberculosis from Crohn's Disease. ( 28045023 )
2017
20
Bilateral Dacryoadenitis: Don't Forget Tuberculosis! ( 27956729 )
2017
21
Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. ( 28089216 )
2017
22
Fumarase Deficiency Causes Protein and Metabolite Succination and Intoxicates Mycobacterium tuberculosis. ( 28219662 )
2017
23
Deregulated lncRNAs in B Cells from Patients with Active Tuberculosis. ( 28125665 )
2017
24
Peritoneal tuberculosis in patients with rheumatoid arthritis undergoing adalimumab treatment. ( 28527603 )
2017
25
Tuberculosis mimicking primary systemic vasculitis: not to be missed! ( 28092221 )
2017
26
Urogenital Tuberculosis. ( 28087922 )
2017
27
Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report. ( 28086756 )
2017
28
Evaluation of five serologic assays for bovine tuberculosis surveillance in domestic free-range pigs from southern Spain. ( 28089289 )
2017
29
Paradoxical reaction associated with cervical lymph node tuberculosis: predictive factors and therapeutic management. ( 27810522 )
2017
30
Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis. ( 28073344 )
2017
31
Evaluation of the XpertAr MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia. ( 28086955 )
2017
32
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. ( 28076011 )
2017
33
Identification of unique essential proteins from a M. tuberculosis F15/LAM4/KZN phage secretome library. ( 28087649 )
2017
34
Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as tuberculosis vaccine. ( 28087528 )
2017
35
Tissue inhibitor of metalloproteinases 1, a novel biomarker of tuberculosis. ( 27959391 )
2017
36
Ocular mycobacteriosis-dual infection of M. tuberculosis complex with M. fortuitum and M. bovis. ( 28091937 )
2017
37
Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory. ( 28499359 )
2017
38
Diagnostic Accuracy of GeneXpert MTB/RIF Assay in Comparison to Conventional Drug Susceptibility Testing Method for the Diagnosis of Multidrug-Resistant Tuberculosis. ( 28081227 )
2017
39
T Cell Responses and Regulation and the Impact of In Vitro IL-10 and TGF-I^ Modulation During Treatment of Active Tuberculosis. ( 27862137 )
2017
40
Mycobacterium tuberculosis multi-drug-resistant strain M induces IL-17(+) IFNI^(-) CD4(+) T cell expansion through an IL-23 and TGF-I^-dependent mechanism in patients with MDR-TB tuberculosis. ( 27681197 )
2017
41
Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. ( 28049176 )
2017
42
The impact of ISGylation during Mycobacterium tuberculosis infection in mice. ( 28087453 )
2017
43
Programmed death-1(+) T cells inhibit effector T cells at the pathological site of miliary tuberculosis. ( 27665733 )
2017
44
Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa. ( 28077475 )
2017
45
Tuberculosis-associated hemophagocytic lymphohistiocytosis with initial presentation of fever of unknown origin in a general hospital: An analysis of 8 clinical cases. ( 28422850 )
2017
46
120 Years of Tuberculosis Research: An Historical Perspective from the Archive of the Journal of Comparative Pathology. ( 28087057 )
2017
47
Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease. ( 27813111 )
2017
48
Diffuse pseudo-tumoral pericardial tuberculosis. ( 28065910 )
2017
49
Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. ( 28049171 )
2017
50
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. ( 28092681 )
2017

Variations for Tuberculosis

Expression for Tuberculosis

Search GEO for disease gene expression data for Tuberculosis.

Pathways for Tuberculosis

Pathways related to Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 B2M CD209 CTSG GNLY IFNG IFNGR1
2
Show member pathways
13.48 IL10 IL18 IL1B TIRAP TLR2 TLR4
3
Show member pathways
13.27 IFNG IFNGR1 IL1B TLR2 TLR4 TLR6
4
Show member pathways
13.08 CD209 IL18 IL1B TIRAP TLR2 TLR4
5
Show member pathways
12.95 B2M GNLY HSPD1 IFNG IL10 IL1B
6
Show member pathways
12.93 IFNG IFNGR1 IL10 IL1B TIRAP TLR2
7
Show member pathways
12.88 CD209 IFNG IFNGR1 IL18 IL1B TLR2
8
Show member pathways
12.78 IL1B TLR2 TLR4 TLR6 TLR9 TNF
9
Show member pathways
12.72 IL1B TIRAP TLR2 TLR4 TLR6 TLR9
10
Show member pathways
12.72 IFNG IFNGR1 IL10 IL18 IL1B TLR2
11
Show member pathways